Evidence map›Paper›PMID 39702287›Full record

ArticleCancer cell international2024

Circulating TERT serves as the novel diagnostic and prognostic biomarker for the resectable NSCLC.

Guanxuan Chen, Shiwen Wang, Qianru Zhang, Junyan Liu, Wanqi Zhu, Xianrang Song, Xingguo Song

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Guanxuan ChenOncology Department, Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning, PR China.
Shiwen WangDepartment of Clinical Laboratory, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, 440 Ji- Yan Road, Jinan, 250117, Shandong Province, PR China.
Qianru ZhangDepartment of Clinical Laboratory, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, 440 Ji- Yan Road, Jinan, 250117, Shandong Province, PR China.
Junyan LiuShandong Provincial Key Laboratory of Precision Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong, PR China.
Wanqi ZhuShandong Provincial Key Laboratory of Precision Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong, PR China.
Xianrang SongShandong Provincial Key Laboratory of Precision Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong, PR China.
Xingguo SongDepartment of Clinical Laboratory, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, 440 Ji- Yan Road, Jinan, 250117, Shandong Province, PR China. xgsong@sdfmu.edu.cn.

Funding

Shandong Natural Science Foundation Innovation and Development Joint Fund ZR2023LZL011Shandong Traditional Chinese Medicine Technology Project M2023-013Taishan Youth Scholar Program of Shandong Province tsqn202312366
6 · The paper itself

Abstract

backgroundTelomerase reverse transcriptase (TERT) is a catalytic subunit of telomerase and required for cancer development. This study aims to reveal its clinical utility for diagnosis and prognosis of resectable NSCLC.

methodsTERT was quantitatively evaluated by the enzyme-linked immunosorbent assay (ELISA) from 69 patients before and after the surgery. The prognostic value was evaluated by disease-free survival (DFS) and overall survival (OS).

resultsCirculating TERT in NSCLC patients were significantly higher than that in the healthy group, possessing the AUC of 0.90. Importantly, TERT change between pre- and post- operation was significantly correlated with OS and DFS (p = 0.022, p = 0.046 respectively), acted as the independent prognostic factors for DFS and OS, indicating it can serve as the promising diagnostic and prognostic biomarker for resectable non-small cell lung cancer (NSCLC).

conclusionsTERT change between pre- and post- resection can serve as the promising biomarker for prognosis of resectable NSCLC.

Indexed as

DiagnosisLeukocyte telomere length (LTL)PrognosisResectable NSCLCTelomerase reverse transcriptase (TERT)

Identifiers

PMID39702287
PMCPMC11661135

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.